Drug comparisons
Linagliptin vs Chlorpropamide
Linagliptin vs Chlorpropamide for type 2 diabetes: DPP-4 inhibitor vs sulfonylurea. Compare efficacy, hypo risk, weight gain, and which may be preferable.
No comparison dimensions are available for this page.
Clinical context
This comparison is triggered when patients or clinicians evaluate switching from an older first-generation sulfonylurea to a modern DPP-4 inhibitor for type 2 diabetes.
Bottom line
Linagliptin generally provides a more favorable benefit-risk profile than Chlorpropamide for most adults with type 2 diabetes, though individual factors must guide the final choice.
All medication comparisons